deltatrials
Completed PHASE3 NCT00097084

Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

Sponsor: Novo Nordisk A/S

Conditions Diabetes Diabetes Mellitus, Type 2
Interventions insulin aspart insulin detemir insulin glargine
Updated 7 times since 2017 Last updated: Jan 26, 2017 Started: Sep 30, 2004 Primary completion: Dec 31, 2005 Completion: Dec 31, 2005

A PHASE3 clinical study on Diabetes and Diabetes Mellitus, Type 2, this trial is completed. The trial is conducted by Novo Nordisk A/S and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novo Nordisk A/S
Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Asheville, United States, Athens, United States, Bergen, Norway, Berlin, United States, Boca Raton, United States, Brest, France, Dallas, United States, Espoo, Finland, Falun, Sweden, Gothenburg, Sweden and 47 more location s